Volume 131, Issue 7 pp. 1384-1392
RESEARCH ARTICLE

Impact of Neoadjuvant Chemotherapy on Perioperative Morbidity in Combined Resection of Rectal Cancer and Liver Metastases

Joy Z. Done

Joy Z. Done

Colorectal Research Unit, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Search for more papers by this author
Angelos Papanikolaou

Angelos Papanikolaou

Colorectal Research Unit, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Department of Surgery, NYU Langone Health, New York, New York, USA

Search for more papers by this author
Miloslawa Stem

Miloslawa Stem

Colorectal Research Unit, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Search for more papers by this author
Shannon N. Radomski

Shannon N. Radomski

Colorectal Research Unit, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Search for more papers by this author
Sophia Y. Chen

Sophia Y. Chen

Colorectal Research Unit, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Search for more papers by this author
Jay R. Maturi

Jay R. Maturi

Colorectal Research Unit, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Search for more papers by this author
Chady Atallah

Chady Atallah

Colorectal Research Unit, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Department of Surgery, NYU Langone Health, New York, New York, USA

Search for more papers by this author
Bashar Safar

Corresponding Author

Bashar Safar

Colorectal Research Unit, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Department of Surgery, NYU Langone Health, New York, New York, USA

Correspondence: Bashar Safar ([email protected])

Search for more papers by this author
First published: 13 January 2025

Poster presentation at the 2023 American Society of Colon & Rectal Surgeons Annual Scientific Meeting in Seattle, WA, June 3−6, 2023.

ABSTRACT

Background and Objectives

Little is known about the relationship between neoadjuvant chemotherapy (NAC) and perioperative morbidity for patients undergoing combined resection of rectal cancer and sLM. The purpose of this study is to determine the impact of NAC on 30-day morbidity for patients who undergo combined resection of primary rectal cancer and sLM.

Materials and Methods

A retrospective cohort study of patients undergoing combined resection of primary rectal cancer and sLM between 2016 and 2020 at participating NSQIP hospitals. Multivariate logistic regression models were used to assess the relationship between NAC and 30-day morbidity rates.

Results

Among 878 patients who underwent combined resection of primary rectal cancer and sLM, 672 (76.54%) received NAC. There were no significant differences in the rates of 30-day overall morbidity between patients who received NAC and those who did not (37.65% vs. 37.68%, p = 0.95). On adjusted analysis, there was no association between receipt of NAC and rates of overall morbidity (adjusted OR = 1.10, 95% CI 0.78−1.56, p = 0.95).

Conclusions

The receipt of NAC does not appear to be associated with increased perioperative morbidity in patients undergoing combined resection of primary rectal cancer and sLM.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The data that support the findings of this study are available upon request from the American College of Surgeons National Surgical Quality Improvement Program (NSQIP).

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.